Li Lu provided commentary on investment risk factors concerning Alnylam Pharmaceuticals on July 17, 2025.
1 report, 1 independent
Updated Jul 17
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Li Lu provided commentary on investment risk factors concerning Alnylam Pharmaceuticals on July 17, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.
- Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.
-
Li Lu
researcher (ORCID 0000-0002-4361-012X)
Nothing else this week.
Coverage
Newest first; wire copies grouped- Simply Wall St.Health Check: How Prudently Does Alnylam Pharmaceuticals (NASDAQ:ALNY) Use Debt? The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says '